$-0.07 EPS Expected for BioLineRx Ltd. (BLRX) as of May, 24

May 16, 2018 - By Julia Grubbs

BioLineRx Ltd. (NASDAQ:BLRX) Corporate Logo

Investors expect BioLineRx Ltd. (NASDAQ:BLRX)’s quarterly earnings on May, 24., according to RTT. Analysts predict $-0.07 earnings per share. That’s $0.01 up or 12.50 % from 2017’s earnings of $-0.08. After $-0.07 EPS report previous quarter, Wall Street now forecasts 0.00 % EPS growth of BioLineRx Ltd.. The stock increased 8.09% or $0.0663 during the last trading session, reaching $0.8863.BioLineRx Ltd. is downtrending after having declined 24.35% since May 16, 2017. BLRX has 1.34M volume or 509.36% up from normal. BLRX underperformed by 35.90% the S&P500.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

A total of 2 analysts rate Biolinerx (NASDAQ:BLRX) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:BLRX) has 9 ratings reports on May 16, 2018 according to StockzIntelligence. On Tuesday, March 6 the stock of BioLineRx Ltd. (NASDAQ:BLRX) earned “Buy” rating by H.C. Wainwright. In Monday, December 4 report Oppenheimer maintained the stock with “Buy” rating. The company rating was maintained by H.C. Wainwright on Monday, December 4. The stock rating was maintained by Oppenheimer with “Buy” on Tuesday, March 20. The stock rating was initiated by Oppenheimer with “Buy” on Thursday, December 21. On Tuesday, November 21 the rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, March 6 Oppenheimer maintained the shares of BLRX in report with “Buy” rating. On Wednesday, January 17 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, December 21 the firm earned “Buy” rating by H.C. Wainwright.

BioLine Rx Ltd, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.The company has $93.94 million market cap. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions.Last it reported negative earnings. The company's other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More recent BioLineRx Ltd. (NASDAQ:BLRX) news were announced by Benzinga.com, Benzinga.com and Benzinga.com. The first one has “40 Stocks Moving In Wednesday’s Mid-Day Session” as a title and was announced on May 16, 2018. The next is “Benzinga Pro’s 5 Stocks To Watch Today” on May 16, 2018. And last was announced on May 16, 2018, called “BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid …”.

BioLineRx Ltd. (NASDAQ:BLRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: